ClinicalTrials.Veeva

Menu

Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies (PEPsy)

C

Centre Hospitalier Universitaire de Saint Etienne

Status

Enrolling

Conditions

Schizophrenia

Treatments

Procedure: MRI

Study type

Observational

Funder types

Other

Identifiers

NCT02670447
2015-A01756-43 (Other Identifier)
1508174

Details and patient eligibility

About

Researchers propose in this project to evaluate predictive factors of non response. It is defined by the lack of symptomatic remission at month 3, for patients presenting a first episode of psychosis. It will be performed on objective markers taken from imagery techniques. The link between evolution of these markers and clinical measures will be studied.

Full description

Recently, radiological markers demonstrated a good capacity to discriminate first episode of psychosis patients, that will show a bad response to treatment. Furthermore, automatic learning methods were recently successfully applied to neurological data, but never for the first episode psychosis patients. These powerful methods are based on multivariate analyses allowing the prediction at an individual stage. The possibility to identify more precisely the population of non-answering patients would allow the adaptation of the support in first attention for these patients, and consequently to perform appropriate cares.

Researchers propose in this project to evaluate predictive factors of non response. It is defined by the lack of symptomatic remission at month 3, for patients presenting a first episode of psychosis. It will be performed on objective markers taken from imagery techniques. The link between evolution of these markers and clinical measures will be studied.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 35 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • men and women aged 18-35 years
  • member or beneficiary of a social security scheme,
  • for women, appropriate contraception will be mandatory, as well as a negative pregnancy test,
  • patients with a diagnosis of schizophrenia, schizoaffective disorder or schizophreniform disorder according to the DMS V
  • having never received anti-psychotic treatment,
  • followed in the hospital or outpatient,
  • having given their written informed consent,
  • that the physical examination revealed no significant clinical abnormalities

Exclusion criteria

  • Female patients of childbearing period without effective contraception (oral, intramuscular hormonal, intrauterine device, or surgical);
  • Patients pregnant or nursing;
  • Presenting a serious somatic or neurological disease, especially Parkinson's disease, epilepsy, debilitating tardive dyskinesia, cardiovascular disease, severe liver or kidney;
  • Featuring against-indication for an MRI; including: metallic foreign body eye or intracranial, pacemaker, heart valve, surgical clips, claustrophobia, large tattoo in the upper part of the body, not compatible with 3T MRI
  • Having a history of alcohol or drug abuse in the past year;
  • Participating in another clinical trial or being in an exclusion period of the previous protocol;
  • Patients likely to exhibit aggressive behavior self according to the judgment of the investigators.

Trial design

80 participants in 1 patient group

First episode of psychosis patients
Description:
Patients with schizophrenia will be studied in this clinical trial, and that have never received anti-psychotic treatment. They will perform an MRI.
Treatment:
Procedure: MRI

Trial contacts and locations

5

Loading...

Central trial contact

Eric FAKRA, MD PhD; Marlène BONNEFOI, Project manager

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems